Inhaled treprostinil for progressive pulmonary fibrosis
Treatments studied
Part of Lungs & breathing clinical trials.
This trial tests an inhaled medication called treprostinil palmitil to see if it can slow the decline of lung function in people with progressive pulmonary fibrosis (PPF), a condition where lung scarring worsens over time. It's for people whose lung disease is getting worse despite standard care, and it may help preserve their breathing ability.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of lung scarring (fibrosis) other than idiopathic pulmonary fibrosis (IPF), confirmed by a CT scan.
- Your lung function (FVC) has been declining over the past 2 years despite standard treatment — for example, a drop of 10% or more, or a smaller drop with worse symptoms or more scarring on scans.
- Your current lung function (FVC) is at least 45% of what's expected for someone your age.
- You are either on a stable dose of an antifibrotic drug (like nintedanib or nerandomilast) for at least 12 weeks, or you have not taken such a drug for at least 8 weeks.
- You cannot have a history of significant pulmonary hypertension (high blood pressure in the lungs) that required treatment.
- You must be able to use an inhaler device and perform breathing tests.
- No recent (within 90 days) sudden worsening of your lung disease or a lung infection (within 30 days).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 trial tests whether inhaled treprostinil can slow progression of lung fibrosis (scarring) that keeps getting worse despite standard care. It also looks at safety, because inhaled medicine can cause side effects and needs careful monitoring.
This study tests an inhaled powder medication called TPIP (treprostinil palmitil inhalation powder) to see if it can improve symptoms and exercise ability in people who have both interstitial lung disease and pulmonary hypertension. The study will compare TPIP against a placebo (a dummy treatment without the active drug) to understand how well it works and if it is safe.
This is an add-on (extension) study testing whether continuing inhaled treprostinil can help people with fibrotic lung disease who took part in earlier related studies. It mainly continues treatment and follow-up for eligible participants.
This program provides access to an inhaled medication called treprostinil for people who have pulmonary hypertension (high blood pressure in the lungs) related to interstitial lung disease (a type of lung scarring). The treatment aims to improve symptoms and quality of life.
This study tests an experimental medicine called HSK44459 to see if it can slow down progressive pulmonary fibrosis (PPF), a condition that causes lung scarring and breathing difficulty. The goal is to learn if the medicine can help people keep more of their lung function compared to a placebo.
This study tests a new dry powder inhaled medicine called LIQ861 for people with pulmonary hypertension related to lung scarring (PH-ILD). If you are already taking an inhaled treprostinil treatment but need better control, this trial may help you switch to a potentially easier-to-use version.
Hear when a new Progressive Pulmonary Fibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.